Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.

[1]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[2]  Jan E Schnitzer,et al.  Overcoming in vivo barriers to targeted nanodelivery. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[3]  S. Mittal,et al.  Adenoviral vector immunity: its implications and circumvention strategies. , 2011, Current gene therapy.

[4]  E. Chang,et al.  Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. , 1999, Human gene therapy.

[5]  J. Gu,et al.  Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  P. Pelicci,et al.  The emerging role of p53 in stem cells. , 2012, Trends in molecular medicine.

[7]  Qi Zhou,et al.  Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. , 2004, Nucleic acids research.

[8]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[9]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[10]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[11]  A. Rait,et al.  A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene , 2004, Gene Therapy.

[12]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[13]  J. Nemunaitis,et al.  Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome. , 2008, Future oncology.

[14]  E. Chang,et al.  Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. , 2002, Human gene therapy.

[15]  David P. Lane,et al.  Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.

[16]  J. Roth,et al.  Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck , 2009, Clinical Cancer Research.

[17]  J. Nemunaitis,et al.  Head and neck cancer: Response to p53‐based therapeutics , 2011, Head & neck.

[18]  H. Shepard,et al.  Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. , 1996, Cancer gene therapy.

[19]  Leaf Huang,et al.  Recent advances in nonviral vectors for gene delivery. , 2012, Accounts of chemical research.

[20]  N. Senzer,et al.  A review of contusugene ladenovec (Advexin) p53 therapy. , 2009, Current opinion in molecular therapeutics.

[21]  J. Roth,et al.  The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. , 1996, Journal of cancer research and clinical oncology.

[22]  C. Dass,et al.  Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy. , 2010, Die Pharmazie.

[23]  E. Chang,et al.  Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[24]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[25]  A. Inga,et al.  Tumour p53 mutations exhibit promoter selective dominance over wild type p53 , 2002, Oncogene.

[26]  A. Gudkov,et al.  The role of p53 in determining sensitivity to radiotherapy , 2003, Nature Reviews Cancer.

[27]  R. Eeles,et al.  p53 therapy in a patient with Li-Fraumeni syndrome , 2007, Molecular Cancer Therapeutics.

[28]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[29]  Gustavo Helguera,et al.  The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.

[30]  E. Chang,et al.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.

[31]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[32]  S. Hirohashi,et al.  Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer , 1991, Japanese journal of cancer research : Gann.

[33]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[34]  J. Roth,et al.  Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.

[35]  J. Eyfjörd,et al.  Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. , 1993, Cancer research.

[36]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Y. Fujiwara,et al.  Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection , 1994, Japanese journal of cancer research : Gann.

[38]  Shuichi Tsutsumi,et al.  A global map of p53-binding sites in the human genome , 2007 .

[39]  T. Daniels,et al.  The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. , 2006, Clinical immunology.

[40]  D. Lane,et al.  On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. , 1995, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[41]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[42]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[43]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[44]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[45]  E. Chang,et al.  Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv , 2001, Molecular medicine.

[46]  Pier Paolo Di Fiore,et al.  The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells , 2009, Cell.

[47]  Qi Zhou,et al.  Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. , 2005, Human gene therapy.

[48]  A. El‐Naggar,et al.  Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. , 2011, The Journal of clinical investigation.

[49]  Qi Zhou,et al.  Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. , 2007, Cancer research.

[50]  S. Lowe,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2011, Nature.